Advertisement
Advertisement
U.S. Markets open in 8 hrs 52 mins
Advertisement
Advertisement
Advertisement
Advertisement

Candel Therapeutics, Inc. (CADL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.4900-0.0100 (-0.29%)
At close: 04:00PM EDT
3.4900 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement

Candel Therapeutics, Inc.

117 Kendrick Street
Suite 450
Needham, MA 02494
United States
617 916 5445
https://www.candeltx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees65

Key Executives

NameTitlePayExercisedYear Born
Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D.Pres, CEO & Director956.8kN/A1961
Dr. Estuardo Aguilar-Cordova Inf., M.D., Ph.D.Founder & Director526.39kN/A1959
Mr. John J. CanepaChief Financial Officer449.12kN/A1956
Ms. Carrie Smith CoxSpecial Advisor to the CEO56.25kN/A1958
Dr. Seshu Tyagarajan Ph.D.Chief Technical & Devel. OfficerN/AN/AN/A
Dr. Francesca Barone M.D., Ph.D.Chief Scientific OfficerN/AN/A1978
Ms. Ileen B. WinickChief People OfficerN/AN/AN/A
Ms. Susan Stewart J.D.Chief Regulatory OfficerN/AN/A1962
Mr. Nathan CaffoChief Bus. OfficerN/AN/A1969
Mr. Stephen Charles RocamboliSec.N/AN/A1972
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

Corporate Governance

Candel Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement